UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
Abstract Background Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1 (UGT1A1) is a predictive biomarker for the side-effects of irinotecan chemotherapy, which reduces the volume of tumors harboring UGT1A1 polymorphisms. We aimed to determine whether UGT1A1 polymorphisms can predic...
Main Authors: | Hideki Matsuoka, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Akihito Horie, Junzo Hamanishi, Tsukasa Baba, Masaki Mandai |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07225-1 |
Similar Items
-
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
by: Takano M, et al.
Published: (2017-02-01) -
Cost-Effectiveness of UGT1A1 Genotyping Prior to Irinotecan Therapy
by: Berryman, Lindsay, et al.
Published: (2007) -
Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature
by: Lia Argevani, et al.
Published: (2020-08-01) -
Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
by: Zhu X, et al.
Published: (2021-03-01) -
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
by: Ryan S. Nelson, et al.
Published: (2021-03-01)